stock performance
Pet Health vs Earnings? Elanco Reverses Trajectory
In Q2 2026, Elanco posted a 32% EBITDA margin, signaling a reversal in its revenue trajectory. The company’s recent gains stem from pet health innovations, stronger drug sales, and strategic market moves that together reshape future earnings outlook. Medical Disclaimer: This article is for informational purposes only and does